Clinical trials: Dengue Hemorrhagic Fever
Dengue, Flavivirus Infections
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
The objective of this observational study of dengue seroprevalence in the metropolitan area of Buenos Aires is to know what percentage of the population has antibodies against dengue in persons 18 years of age or older who are…
- Trial name
- NCT05919277
- Testing
- Dengue Immunoglobulin G antibodies performed with ELISA
- Where
- Argentina
- Volunteers
- 1,487 people
- Sponsor
- Fundacion GESICA
Dengue
The Effect of Chloroquine in the Treatment of Patients With Dengue
The objective of this study was to evaluate the effect of chloroquine in the treatment of patients with dengue.
- Trial name
- NCT00849602
- Testing
- Chloroquine
- Where
- Brazil
- Volunteers
- 132 people
- Sponsor
- University of Sao Paulo
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.
- Trial name
- NCT01134263
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- Where
- 8 sites in Australia
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Dengue is one of the most epidemiologically and clinically relevant arboviral diseases, affecting half of the global population.
- Trial name
- RIMVADE (NCT07158190)
- Testing
- Vaccine
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Dengue
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.
- Trial name
- NCT02406729
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 17 sites in Brazil
- Volunteers
- 16,935 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Dengue
Insecticidal School Uniforms for Dengue Prevention in Thailand
This is a randomised controlled trial that will be conducted in eastern Thailand in a group of schools with approximately 2,000 students aged 7-15 years.
- Trial name
- DengueTools (NCT01563640)
- Testing
- permethrin insecticide, washing
- Where
- Thailand
- Volunteers
- 1,825 people, healthy volunteers welcome
- Sponsor
- Umeå University
Dengue Virus, Dengue Fever
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
This is part of an ongoing effort to develop a satisfactory dengue vaccine: Primary objective: To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00740155
- Testing
- Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero), Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero), Tetravalent CYD-1,2,3,4 Dengue (Vero)
- Where
- 2 sites in Mexico
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
Dengue viruses can cause dengue fever and other more severe forms of disease. This study will evaluate the safety and immune response to two doses of a dengue virus vaccine given 12 months apart in healthy adults.
- Trial name
- NCT01782300
- Testing
- TV003 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Identification of Risk Determinants of Dengue Transmission Through Landscape Analysis
This retrospective observational study aims to determine the probability of the risk of dengue transmission through a model based on epidemiological, entomological, socioeconomic, demographic, and landscape variables in the El…
- Trial name
- IRDDENGUELA (NCT05893134)
- Testing
- Risk Assessment
- Where
- Mexico
- Volunteers
- 196 people
- Sponsor
- Instituto Mexicano del Seguro Social
Dengue, Chikungunya Virus Infection
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello.
- Conditions
- Dengue, Chikungunya Virus Infection, Zika Virus Infection
- Trial name
- WMP-COL (NCT03631719)
- Testing
- Wolbachia-carrying Ae.aegypti mosquitoes
- Where
- Colombia
- Volunteers
- 834 people
- Sponsor
- Universidad de Antioquia
Dengue
Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico
Background: Dengue continues to be a high priority disease for public health in tropical and subtropical countries, where vector control measures have not had the expected impact on transmission.
- Trial name
- NCT04947111
- Testing
- Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
- Where
- Mexico
- Volunteers
- 1,960 people, healthy volunteers welcome
- Sponsor
- Mexican Society of Public Health
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue, Vector Borne Diseases
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities.
- Conditions
- Dengue, Vector Borne Diseases, Arbovirus Infections, Zika
- Trial name
- NCT06268691
- Testing
- Insecticide Coating INESFLY
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Rocio Cardenas Sanchez
Dengue Fever
Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.
- Trial name
- NCT00688389
- Testing
- case/control
- Where
- Taiwan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital